Dewit L
Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403-26. doi: 10.1016/0360-3016(87)90015-0.
Cis-diamminedichloroplatinum (II) (c-DDP), a highly effective cytostatic drug, is increasingly used in combination with irradiation both in the laboratory and in patients. This review aims at a critical reassessment of the potential role of this drug as a "radiosensitizer." The opinion about c-DDP being an effective hypoxic cell radiosensitizer in bacteria was substantiated in some studies on mammalian cells in culture but not in others. More powerful mechanisms of radiation enhancement, which are not yet fully explored, may be depletion of endogenous thiols, inhibition of cellular repair processes, and proliferation inhibition. The effects of c-DDP in combination with irradiation in experimental tumors seem to vary between different investigators and between different tumor systems. Occasionally, supra-additive effects have been observed in some animal tumors. This stresses the need for testing this combination treatment in various tumor types, preferentially of human origin. In normal tissues, the effects are, to a large extent, explained by independent cell killing by each agent. A substantial number of clinical pilot studies have shown that the combination treatment is feasible, but the results of ongoing phase III trials will be needed to assess the potential therapeutic benefit of this combined treatment modality.
顺二氯二氨铂（II）（c-DDP）是一种高效的细胞抑制药物，在实验室和患者中越来越多地与放疗联合使用。本综述旨在对该药物作为“放射增敏剂”的潜在作用进行批判性重新评估。关于c-DDP在细菌中是一种有效的乏氧细胞放射增敏剂的观点，在一些关于培养的哺乳动物细胞的研究中得到了证实，但在其他研究中则未得到证实。尚未充分探索的更强有力的辐射增强机制可能包括内源性硫醇的消耗、细胞修复过程的抑制和增殖抑制。在实验性肿瘤中，c-DDP与放疗联合使用的效果在不同研究者和不同肿瘤系统之间似乎有所不同。偶尔，在一些动物肿瘤中观察到超相加效应。这强调了需要在各种肿瘤类型（优先为人源肿瘤）中测试这种联合治疗。在正常组织中，其效应在很大程度上可由每种药物独立杀伤细胞来解释。大量临床前期研究表明联合治疗是可行的，但需要正在进行的III期试验结果来评估这种联合治疗方式的潜在治疗益处。
